This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
by Zacks Equity Research
Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of +26.09% and -4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
by Zacks Equity Research
Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
by Zacks Equity Research
CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.
Should Invesco S&P SmallCap Momentum ETF (XSMO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for XSMO
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPSE
Is Invesco S&P SmallCap Quality ETF (XSHQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XSHQ
Should Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GSSC
Should Invesco S&P SmallCap Quality ETF (XSHQ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for XSHQ
Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for May 29th
by Zacks Equity Research
CORT, AETUF and MITT have been added to the Zacks Rank #5 (Strong Sell) List on May 29, 2025.
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
by Zacks Equity Research
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025. Stock down.
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 0% and 11.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CORT's first-quarter 2025 earnings call, investors are likely to focus on the sales performance of its Cushing's syndrome drug, Korlym.
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should iShares Core S&P Small-Cap ETF (IJR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJR
Should Invesco S&P SmallCap Momentum ETF (XSMO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for XSMO
Is Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for GSSC
Should iShares S&P Small-Cap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
by Zacks Equity Research
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
by Zacks Equity Research
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
by Zacks Equity Research
Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
by Ekta Bagri
CORT and AXSM are in the spotlight this week following the announcement of study data.
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.